2 Abstract:
Increased rates of bone marrow transplant (BMT) graft rejection are observed in patients whose illnesses necessitate chronic transfusion prior to BMT, such as sickle cell disease, thalassemia, or aplastic anemia. Because BMTs in this setting are routinely HLA matched, any immunization responsible for increased rejection is likely against minor histocompatibility antigens (mHAs). It has been assumed that contaminating leukocytes in red blood cell (RBC) units are the main source of immunization to mHAs. However, in this report we demonstrate that antigens on donor RBC are presented in the MHC class I pathway of recipient antigen presenting cells, resulting in activation and expansion of recipient CD8 + T cells specific for donor mHAs. Since human hematopoietic progenitor cells express many of the known mHAs, this observation provides a mechanism by which chronic transfusion of even stringently leukoreduced RBC may result in sufficient mHA immunization to increase the frequency of BMT rejection.
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Introduction:
Bone marrow transplantation (BMT) is now standard therapy for a variety of hematological malignancies and also represents a cure for certain non-malignant hematological disorders. To avoid the morbidity and mortality associated with stringent myeloablative therapies used to treat neoplasia, milder and less immunosuppressive conditioning regimens have been designed for treating non-malignant illnesses. However, high rates of graft rejection are observed in patients whose illnesses necessitate chronic transfusion of red blood cells (RBC) prior to BMT, such as sickle cell disease, thalassemia, or aplastic anemia [1] [2] [3] .
It has been proposed that chronic transfusion immunizes the recipient to multiple donor antigens, which contributes to subsequent rejection of bone marrow grafts. Because BMTs in the non-malignant setting are routinely HLA identical transplants, it is unlikely that immunization against MHC molecules plays a role in graft rejection. However, immunization against minor histocompatibility antigens (mHAs) is known to occur in response to chronic transfusion 4 .
mHAs are polymorphic peptides from allelic variants of normal human proteins, which are displayed by MHC molecules and elicit a specific MHC-restricted T cell response. 5 It has been assumed that contaminating leukocytes in RBC units were the main source of immunization to mHAs. Accordingly, it had been anticipated that the recent implementation of leukoreduced products would decrease the incidence of matched related marrow graft rejection in multiply transfused patients. However, a recent analysis of patients undergoing transplantation for severe aplastic anemia performed by the International Bone Marrow
Transplant Registry, suggests that this is not the case (John T. Horan, Unpublished data).
We hypothesized that transfusion of RBC is sufficient to immunize against mHAs.
Although exogenous antigens are typically processed and presented through MHC class II 
Materials and Methods:
Crosslinking of OVA or HEL to the RBC surface. 2-pyridyldithiol groups were added to OVA (15mg/ml) or HEL (5mg/ml) by incubating with 0.6mg/ml succinimidyl 6-(3- For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
Results and Discussion:
To test our hypothesis, we generated units of leukoreduced murine RBC that carry chicken ovalbumin (OVA) or hen egg lysozyme (HEL) as model antigens. Crosslinking of HEL and OVA to the RBC was confirmed by staining with rabbit anti-HEL or rabbit anti-OVA and analyzing by flow cytometry. (Figure 1A and 1B). To confirm that the crosslinked RBC maintained the ability to circulate, OVA-RBC or uncrosslinked RBC were labeled with the fluorescent dyes DiO and CM-DiI, respectively as previously described 7 and were transfused as a 1:1 mixture into recipient mice. 24 hours after transfusion, recipient mice were bled and transfused cells were visualized by flow cytometry ( Figure 1C ). Transfused OVA-RBC were circulating at this time and OVA was stable on the RBC surface ( Figure 1D ), however there were fewer modified cells than unmodified cells, indicating increased clearance of modified cells.
Longer-term studies revealed that OVA-RBC have a decreased circulatory life-span compared to unmodified cells, but continue to circulate for approximately 2 weeks with stable OVA protein on the surface (data not shown).
To determine the quantity of OVA on the cell surface, RBC ghosts were prepared from OVA crosslinked RBC (OVA-RBC) and were then subjected to western blot analysis with anti-OVA. Under reducing conditions, OVA is easily detected from OVA-RBC ( Figure 1E ). In addition, essentially all of the observed OVA is covalently bound to the RBC by disulfide bonds, as only a very weak non-specific band is observed with the molecular weight of OVA under non- 
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. RBC ghosts were prepared by hypotonic lysis and were subjected to western blot with anti-OVA under reducing (E) or non-reducing conditions (F). Standard curves of OVA were also generated using western blots. To control for any changes in OVA immunoreactivity as a result of the crosslinker, the OVA standard curve was generated using unreacted LC-SPDP modified OVA. 
Figure 2 Expansion of OT-I T cells in Response to

